Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.
A multidrug resistance phenotype is frequently observed in animal and human cell lines selected for in vitro resistance to a single chemotherapeutic agent. Overexpression of a highly conserved cell-surface glycoprotein (P-glycoprotein) is consistently associated with this phenotype in these mutant lines. A monoclonal antibody against P-glycoprotein was used to examine tumor samples from five patients with advanced ovarian cancer for evidence of P-glycoprotein overexpression. High levels of P-glycoprotein were detected in samples from two patients suggesting that a multidrug resistance mutation may also occur in ovarian cancer. This finding has broad implications for the understanding of nonresponse to chemotherapy in a variety of human neoplasms, and may provide a rational explanation for failure of chemotherapy in treatment of advanced ovarian cancer.
Bell
D R
DR
Gerlach
J H
JH
Kartner
N
N
Buick
R N
RN
Ling
V
V
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000032:analysis* / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D005819:Genetic Markers; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000032:analysis* / Q000188:drug therapy; D010641:Phenotype
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D005819:Genetic Markers; D006023:Glycoproteins; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D008558:Melphalan